Hims & Hers Health (NYSE:HIMS) Jumps 40% After Projecting US$2.3 Billion Revenue for 2025
Hims & Hers Health (NYSE:HIMS) experienced a 40% increase in share price last quarter, possibly fueled by strong financial performance and future growth projections. The company announced earnings on ...
Hims & Hers' Fall From Grace Is Warranted - Still No Margin Of Safety
Discover why Hims & Hers faces steep corrections amid GLP-1 headwinds and valuation concerns, despite promising FY2024 growth ...
Hims & Hers: A Generational Dip-Buying Opportunity
Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...
Hims & Hers Stocks Sinks Despite Huge Revenue Growth. Is This a Buying Opportunity in the Stock?
Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (NYSE: HIMS) ...
Why Hims & Hers Health Stock Sank This Week
Shares of Hims & Hers Health (NYSE: HIMS) sank 10.5% this week, according to data from S&P Global Market Intelligence. The ...
Can Telehealth Frontrunner Hims & Hers Health Bounce Back from its Q4 Bombshell?
Hims & Hers Health (HIMS) is an intriguing stock strategically positioned in the rapidly expanding telehealth market. However, this week’s ...
Hims & Hers Health (NYSE:HIMS) Price Target Raised to $40.00
Hims & Hers Health (NYSE:HIMS – Free Report) had its price objective hoisted by Leerink Partners from $24.00 to $40.00 in a report published on Tuesday,Benzinga reports. They currently have a market ...
Modern Healthcare4d
GLP-1 compounding pharmacies sue FDA over shortage decision
Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...
Best Healthcare Stocks To Keep An Eye On – February 25th
Alphabet, Hims & Hers Health, and UnitedHealth Group are the three Healthcare stocks to watch today, according to MarketBeat’s stock screener tool. Healthcare stocks are shares in companies that ...
Why Hims & Hers Stock Has Further to Fall: Heard on the Street
Stock in Hims & Hers Health was bound to tumble once it could no longer sell compounded versions of the weight-loss drug Wegovy at scale. But with lofty expectations about its remaining anti-obesity ...
Hims & Hers Health, Inc.: Jim Cramer Warns ‘The Gravy Train Might Be Over’ After FDA’s Ozempic Update
We recently published a list of Jim Cramer on 10 Stocks With The Biggest Declines Last Week. In this article, we are going to ...
Hims & Hers can't sell off-brand Ozempic forever. But it can still sell these weight loss drugs
Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...